Skip to content

Efficacy of Social Cognition Training in Schizophrenia

Efficacy of Social Cognition Training in Schizophrenia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00587561
Enrollment
51
Registered
2008-01-07
Start date
2008-01-31
Completion date
2023-12-31
Last updated
2025-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

schizophrenia, social cognition, cognition, treatment, outcome

Brief summary

The term social cognition refers to how social information is processed. Individuals with schizophrenia and schizoaffective disorder have been shown to have significant deficits in social cognition. Moreover, it has been speculated that these deficits may in turn have a negative impact on their overall functioning. Behavioral interventions targeting social cognition are just beginning to emerge, and there is a need to evaluate their efficacy. Objectives: This is a small trial evaluating the efficacy of social cognition interaction training (SCIT) an experimental behavioral treatment for improving social cognition in schizophrenia. Research Design and Methodology: Approximately 48 participants with schizophrenia-spectrum disorders will be randomized into one of two conditions: 1) a 20 to 24 session manualized social cognition interaction training group (SCIT), or 2) wait-list control. Pre-and post-group therapy assessments of symptoms, social cognition, basic cognition, and community function will be conducted. Data obtained from this study will allow us to determine the efficacy of SCIT training in improving symptom, cognitive, and functional measures.

Interventions

BEHAVIORALSocial Cognition Interaction Training

manualized group therapy

BEHAVIORALWLC

wait-list control for 6 months, followed by the experimental group therapy

Sponsors

VA Connecticut Healthcare System
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of schizophrenia or schizoaffective disorder * Age between 18 and 65 * minimum of 30 days since discharge from last hospitalization * minimum of 30 days since last change in psychiatric medications * no housing changes in the past 30 days

Exclusion criteria

* current diagnosis of alcohol or substance abuse/dependence * history of brain trauma or neurological disease * mental retardation or developmental disability * auditory or visual impairment that would interfere with study procedures

Design outcomes

Primary

MeasureTime frameDescription
Social Cognitive Measures6 months - baselinechange score for Facial Emotion Identification Task (FEIT), FEIT scores range from 0-19 with higher scores indicating better performance, higher change scores indicate greater improvement

Secondary

MeasureTime frameDescription
Basic Cognitive Measures6 months - baselinechange score on Matrics Consensus Cognitive Battery (MCCB) 6 domain composite average t-score, t-score mean = 50 and SD=10, higher change scores indicate greater improvement; please note outcome is not a t-score itself but a change in t-score

Countries

United States

Participant flow

Pre-assignment details

Our initial plan had been to recruit and enroll 48 participants. 67 volunteers were assessed for eligibility. Of those, 9 did not meet inclusion criteria and 7 declined to participate after learning more about the study. Our initial plan had been to randomized 48 volunteers however due to concerns about potential drop-out, we recruited and randomized 51 participants.

Participants by arm

ArmCount
Intervention
20-26 sessions of a manualized group treatment called social cognition interaction training (0 - 6 months), then crossed-over to treatment as usual.
25
Waitlist Control
6 months of treatment as usual followed by Social Cognition Interaction Training
26
Total51

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up64

Baseline characteristics

CharacteristicWaitlist ControlInterventionTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
26 Participants25 Participants51 Participants
Age, Continuous49.96 years
STANDARD_DEVIATION 9.15
45.56 years
STANDARD_DEVIATION 10.97
47.80 years
STANDARD_DEVIATION 10.23
Region of Enrollment
United States
26 participants25 participants51 participants
Sex: Female, Male
Female
10 Participants10 Participants20 Participants
Sex: Female, Male
Male
16 Participants15 Participants31 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 250 / 250 / 260 / 26
other
Total, other adverse events
0 / 250 / 250 / 260 / 26
serious
Total, serious adverse events
2 / 250 / 251 / 260 / 26

Outcome results

Primary

Social Cognitive Measures

change score for Facial Emotion Identification Task (FEIT), FEIT scores range from 0-19 with higher scores indicating better performance, higher change scores indicate greater improvement

Time frame: 6 months - baseline

ArmMeasureValue (MEAN)Dispersion
Social Cognition Interaction TrainingSocial Cognitive Measures0.11 score on a scaleStandard Deviation 2
Waitlist ControlSocial Cognitive Measures-1.68 score on a scaleStandard Deviation 2.57
Secondary

Basic Cognitive Measures

change score on Matrics Consensus Cognitive Battery (MCCB) 6 domain composite average t-score, t-score mean = 50 and SD=10, higher change scores indicate greater improvement; please note outcome is not a t-score itself but a change in t-score

Time frame: 6 months - baseline

ArmMeasureValue (MEAN)Dispersion
Social Cognition Interaction TrainingBasic Cognitive Measures1.61 score on a scaleStandard Deviation 7.42
Waitlist ControlBasic Cognitive Measures0.81 score on a scaleStandard Deviation 5.3

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026